Join Growin Stock Community!

Instil bio, inc.TIL.US Overview

US StockHealthcare
(No presentation for TIL)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

TIL AI Insights

TIL Overall Performance

TIL AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

TIL Recent Performance

-8.25%

Instil bio, inc.

0.05%

Avg of Sector

-0.31%

S&P500

TIL PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

TIL Key Information

TIL Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

TIL Profile

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

Price of TIL

TIL FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

TIL Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-11.07
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
55329.79
PB Ratio
0.51
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-11.07
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
55329.79
PB Ratio
0.51
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is TIL's latest earnings report released?

    The most recent financial report for Instil bio, inc. (TIL) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating TIL's short-term business performance and financial health. For the latest updates on TIL's earnings releases, visit this page regularly.

  • How much cash does TIL have?

    At the end of the period, Instil bio, inc. (TIL) held Total Cash and Cash Equivalents of 6.08M, accounting for 0.03 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is TIL's EPS continuing to grow?

    According to the past four quarterly reports, Instil bio, inc. (TIL)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -2.01. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of TIL?

    Instil bio, inc. (TIL)'s Free Cash Flow (FCF) for the period is -10.56M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 47.56% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.